Sunday 13 July 2014
Ibrutinib is an inhibitor of the enzyme Bruton’s tyrosine kinase (BTK). Ibrutinib is currently under development by Pharmacyclics, Inc and Johnson & Johnson’s Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton’s tyrosine kinase (BTK).
Ibrutinib, (also known as PCI-32765 and marketed in the U.S. under the name Imbruvica) is an anticancer drug targeting B-cell malignancies.
It was approved by the US FDA and UE for the treatment of mantle cell lymphoma (MCL) and for the treatment of chronic lymphocytic leukemia (CLL).